NCT01222455

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

An Open-label, Single-center Study to Assess the Pharmacokinetics of R406 in Subjects With Hepatic Impairment and in Healthy Subjects Following Administration of a Single Dose of Fostamatinib Disodium 150 mg

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function. The study will also evaluate safety and tolerability in subjects with hepatic impairment.

Conditions

• Hepatic Impairment
• Healthy Volunteers
• Pharmacokinetics
• Amount of R406 in Blood

Interventions

Type	Name	Description
DRUG	Fostamatinib	Oral tablets, single dose

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-10-18
• Last updated: 2011-07-06

Locations

1 site across 1 country: United States